Arne Stman

Title: Arne Stman: Innovator in Platelet Derived Growth Factor Research

Introduction

Arne Stman is a notable inventor based in Uppsala, Sweden. He has made significant contributions to the field of biochemistry, particularly in the area of platelet derived growth factors. With a total of 2 patents, his work has implications for cancer research and therapeutic applications.

Latest Patents

Stman's latest patents include innovations related to platelet derived growth factor antagonists and agonists. The first patent describes antagonists for PDGF, which contain amino acids and may exist as monomers or dimers. These dimers are particularly effective as they bind to PDGF receptors while preventing the dimerization of the bound receptors. This dimerization is essential for the PDGF effect, thus showcasing the antagonistic properties of the invention. Additionally, the patent outlines nucleic acid sequences for producing these antagonists and cell lines transfected with the material.

The second patent focuses on PDGF modifiers, which are peptides derived from wild type PDGF monomers. These peptides can function as either agonists or antagonists, with various applications described. The patent also details recombinant methods for production, including PDGF-B agonists that comprise specific amino acids with substitutions at certain cysteine residues. This invention provides methods for inducing receptor dimerization and autophosphorylation in cells with PDGF-.beta. receptors.

Career Highlights

Arne Stman is affiliated with the Ludwig Institute for Cancer Research Limited, where he continues to advance his research in platelet derived growth factors. His work is pivotal in understanding the mechanisms of cancer and developing potential therapeutic strategies.

Collaborations

Stman collaborates with esteemed colleagues, including Maria Andersson and Gudrun Backstrom, who contribute to his research endeavors.

Conclusion

Arne Stman's innovative work in the field of platelet derived growth factors has led to significant advancements in biochemistry and cancer research. His patents reflect a deep understanding of the molecular mechanisms involved, paving the way for future therapeutic developments.